Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it was informed on 7 February 2017 that Dr Nick Plowman, Chairman of the Company’s medical advisory board, became a significant shareholder on 6 June 2016 and, following subsequent share purchases, currently holds 2,636,799 ordinary shares of 25 pence each in the Company, representing 3.6% of the issued share capital of the Company.
Advanced Oncotherapy plc is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy’s team “ADAM”, based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies. The company will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.
